RTOG

RTOG
Name	Radiation Therapy Oncology Group
Abbreviation	RTOG
Formation	1968
Type	Cooperative group
Headquarters	Philadelphia, Pennsylvania
Location	United States
Fields	Radiation oncology, clinical trials
Parent organization	National Cancer Institute

RTOG The Radiation Therapy Oncology Group was a cooperative clinical trials group focusing on radiotherapy and combined-modality treatment for cancer. It coordinated multicenter studies across institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Mayo Clinic, and Dana–Farber Cancer Institute, contributing protocols that influenced standards used at centers including Johns Hopkins Hospital, Cleveland Clinic, and Stanford Health Care. The group interfaced with regulatory and research organizations like the National Institutes of Health, Food and Drug Administration, American Society for Radiation Oncology, and international partners such as European Organisation for Research and Treatment of Cancer.

History

RTOG originated in the late 1960s amid expansions at the National Cancer Institute and parallel efforts by institutions including University of Pennsylvania, Yale School of Medicine, Harvard Medical School, and Columbia University Irving Medical Center. Early protocols reflected collaborations with centers such as Brigham and Women's Hospital and Roswell Park Comprehensive Cancer Center, and were influenced by radiobiology advances from laboratories at Cold Spring Harbor Laboratory and Lawrence Berkeley National Laboratory. Over decades it engaged in trials with oncology leaders including Bernard Fisher, Paul Carbone, and Francis Collins-era NIH initiatives, aligning with cooperative groups like Children's Oncology Group and Cancer and Leukemia Group B. Milestones included large randomized trials for malignancies treated at Memorial Hospital, adoption of imaging techniques from Massachusetts General Hospital, and integration of dose-fractionation research from University of Chicago.

Organization and Governance

RTOG governance combined scientific leadership from principal investigators at institutions such as University of California, San Francisco, University of Michigan, University of Pittsburgh Medical Center, and Northwestern Memorial Hospital. Committees reflected expertise from departments at Vanderbilt University Medical Center, University of Texas Southwestern Medical Center, and Emory University School of Medicine. Oversight involved federal agencies including National Cancer Institute program officers, compliance with Office for Human Research Protections guidelines, and coordination with ethics boards at academic centers like University of Wisconsin School of Medicine and Public Health. Scientific advisory input included representatives from American College of Radiology, Society of Surgical Oncology, and American Society of Clinical Oncology.

Clinical Trials and Research Contributions

The group conducted randomized trials in disease sites treated at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Mayo Clinic for cancers such as glioblastoma, non-small-cell lung cancer, head and neck cancer, cervical cancer, and prostate cancer. Trials incorporated imaging from Massachusetts General Hospital and biomarker work linked to investigators at Fred Hutchinson Cancer Research Center and Salk Institute. RTOG studies informed chemoradiation regimens contemporaneous with work at Stanford University School of Medicine and systemic therapy trials run with partners like Pfizer and Novartis. Publications appeared in journals including The New England Journal of Medicine, Journal of Clinical Oncology, and The Lancet Oncology, and were cited alongside meta-analyses from Cochrane Collaboration.

Major Protocols and Treatment Standards

Key protocols established by the group influenced fractionation and dose constraints used at centers such as UCLA Medical Center and Mount Sinai Hospital. Standard-setting trials addressed postoperative radiotherapy paradigms similar to approaches at University of California, Los Angeles, and concurrent chemoradiation strategies paralleling oncology practice at Memorial Sloan Kettering Cancer Center. Protocols interacted with staging systems from American Joint Committee on Cancer and radiotherapy planning standards from International Commission on Radiation Units and Measurements. Dosimetric work referenced quality assurance programs analogous to those at Radiological Society of North America and incorporated contouring atlases used by sites including Hackensack University Medical Center.

Collaborations and Networks

RTOG partnered with cooperative groups including EORTC, SWOG, GOG (now NRG Oncology affiliations), and international consortia at institutions such as Royal Marsden Hospital, Christie NHS Foundation Trust, and Peter MacCallum Cancer Centre. Data-sharing occurred with repositories like The Cancer Genome Atlas and collaborative initiatives involving Patient-Centered Outcomes Research Institute and pharmaceutical partners including Eli Lilly and Roche. Training and education links extended to programs at Memorial Hospital West, Johns Hopkins Oncology Center, and fellowship exchanges with centers like Karolinska Institutet.

Impact on Radiation Oncology Practice

Clinical evidence from RTOG trials influenced guidelines promulgated by bodies such as National Comprehensive Cancer Network, American Society of Clinical Oncology, and American College of Radiology. Implementation of trial-derived standards occurred at hospitals including Barnes-Jewish Hospital, St. Jude Children's Research Hospital, and Kaiser Permanente facilities. Advances impacted radiotherapy technologies developed at companies like Varian Medical Systems and Elekta, and informed practice patterns reported in registries maintained by SEER Program and quality metrics from Centers for Medicare & Medicaid Services.

Criticisms and Controversies

Critiques mirrored broader debates involving cooperative groups such as SWOG and EORTC: trial generalizability to community settings like Community Oncology Alliance clinics, slow accrual in rare cancers treated at specialty centers such as Memorial Sloan Kettering Cancer Center, and challenges integrating novel agents from biotechnology firms including Amgen and Genentech. Ethical discussions referenced oversight by Institutional Review Boards at institutions like University of California, San Diego School of Medicine and data-sharing tensions with repositories like dbGaP. Methodological disputes paralleled controversies in oncology trials involving notable figures and trials at Dana–Farber Cancer Institute and debates in journals such as JAMA.

Category:Clinical research organizations